TY  - JOUR
AU  - Salas-Benito, Diego
AU  - Conde, Enrique
AU  - Tamayo-Uria, Ibon
AU  - Mancheño, Uxua
AU  - Elizalde, Edurne
AU  - Garcia-Ros, David
AU  - Aramendia, Jose M
AU  - Muruzabal, Juan C
AU  - Alcaide, Julia
AU  - Guillen-Grima, Francisco
AU  - Minguez, Jose A
AU  - Amores-Tirado, Jose
AU  - Gonzalez-Martin, Antonio
AU  - Sarobe, Pablo
AU  - Lasarte, Juan J
AU  - Ponz-Sarvise, Mariano
AU  - De Andrea, Carlos E
AU  - Hervas-Stubbs, Sandra
PY  - 2021
DO  - 10.1038/s41416-020-01218-4
UR  - https://hdl.handle.net/10668/26672
T2  - British journal of cancer
AB  - Adoptive immunotherapy with tumour-infiltrating lymphocytes (TIL) may benefit from the use of selective markers, such as PD-1, for tumour-specific T-cell enrichment, and the identification of predictive factors that help identify those patients...
LA  - en
KW  - Biomarkers, Tumor
KW  - CD8-Positive T-Lymphocytes
KW  - Female
KW  - Follow-Up Studies
KW  - Gene Expression Regulation, Neoplastic
KW  - Humans
KW  - Lymphocytes, Tumor-Infiltrating
KW  - Ovarian Neoplasms
KW  - Phenotype
KW  - Prognosis
KW  - Programmed Cell Death 1 Receptor
KW  - Retrospective Studies
TI  - The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes.
TY  - research article
VL  - 124
ER  -